UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000039104
Receipt number R000044597
Scientific Title Exploratory study of rehabilitation during hemodialysis and nutrition therapy for hemodialysis patients with sarcopenia
Date of disclosure of the study information 2020/01/10
Last modified on 2023/01/11 11:41:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory study of rehabilitation during hemodialysis and nutrition therapy for hemodialysis patients with sarcopenia

Acronym

Exploratory study of rehabilitation during hemodialysis and nutrition therapy for hemodialysis patients with sarcopenia

Scientific Title

Exploratory study of rehabilitation during hemodialysis and nutrition therapy for hemodialysis patients with sarcopenia

Scientific Title:Acronym

Exploratory study of rehabilitation during hemodialysis and nutrition therapy for hemodialysis patients with sarcopenia

Region

Japan


Condition

Condition

End-stage Kidney Disease (on Hemodialysis)

Classification by specialty

Nephrology Rehabilitation medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To date, the applicant has studied the effects of combined rehabilitation and nutritional therapy during hemodialysis on hemodialysis patients with sarcopenia in a single institutional cohort, and reported that sarcopenia improves three months later. The purpose of this study is to expand the feasibility and generalization of single-center intervention studies to multiple centers.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Sarcopenia improvement in study subjects after 6 months

Key secondary outcomes

Changes in various blood data, body components (lower limb muscle mass, upper limb muscle mass, skeletal muscle index), MIS (Malnutrition Inflammation Score), GNRI (Geriatric Nutritional Risk Index), QIDS-J (Quick Inventry of Depressive Symptomatology)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food Device,equipment

Interventions/Control_1

An interventional study with general rehabilitation performed during dialysis and already commercially available amino jelly leucine 40 (per 100 g: energy 30 kcal, protein 3.0 g, lipid 0 g, carbohydrate 9.7 g, water 87 g)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

Patients who have undergone maintenance hemodialysis at Sapporo Medical University Hospital, Obihiro Kosei Hospital, Teine Keijinkai Hospital, or JR Sapporo Hospital, and who obtained consent from patients diagnosed with sarcopenia

Key exclusion criteria

Excludes limb deficiency, history of orthopedic surgery within 3 months, age under 18, age 90 and older, history of malignant disease, history of spinocerebellar degeneration, and pregnant women

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Masayuki
Middle name
Last name Koyama

Organization

Sapporo Medical University, School of Medicine

Division name

Department of Public Health and Department of Cardiovascular, Renal and Metabolic Medicine

Zip code

060-8543

Address

South-1, West-17, Chuo-ku, Sapporo

TEL

+81-11-611-2111(27420)

Email

masa3yuki3@sapmed.ac.jp


Public contact

Name of contact person

1st name Masayuki
Middle name
Last name Koyama

Organization

Sapporo Medical University, School of Medicine

Division name

Department of Public Health and Department of Cardiovascular, Renal and Metabolic Medicine

Zip code

060-8543

Address

South-1, West-17, Chuo-ku, Sapporo

TEL

+81-11-611-2111(27420)

Homepage URL


Email

masa3yuki3@sapmed.ac.jp


Sponsor or person

Institute

Sapporo Medical University, School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science(JSPS)

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Sapporo Medical University Hospital IRB

Address

South-1, West-16, Chuo-ku, Sapporo

Tel

+81-11-611-2111 ext. 31470

Email

ji-rskk@sapmed.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 01 Month 10 Day


Related information

URL releasing protocol

https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044597

Publication of results

Unpublished


Result

URL related to results and publications

https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-19K19872/

Number of participants that the trial has enrolled

3

Results

At baseline, 4 of 16 hemodialysis patients (age 71.5 [Q1 64.8, Q3 78.0] years, 50% female) had sarcopenia based on AWGS criteria.
Consent was obtained for 3 of the 16 patients, and the "dialysis rehabilitation (nutritional therapy + exercise therapy)" indicated in this study was implemented. No improvement in sarcopenia, the primary endpoint, was obtained, but this was thought to be largely a matter of sample size.

Results date posted

2023 Year 01 Month 11 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Prevalence of hemodialysis patients with sarcopenia
At baseline, 4 of 16 hemodialysis patients (age 71.5 years [Q1 64.8, Q3 78.0], 50% female) had sarcopenia based on AWGS criteria.

Participant flow

In the latter half of the first year of the study, the impact of the novel coronavirus infection (COVID-19) pandemic made it difficult to conduct the study. The situation of the outbreak of clusters at each dialysis facility made it extremely difficult to conduct rehabilitation, which is the core of this study, and it became impossible to accumulate the number of cases that had been planned for the study. Although only one facility was able to conduct infection control precisely and obtain the consent of the ethics committee, and only a few of those cases were able to obtain individual consent, we analyzed as many cases as possible.

Adverse events

none

Outcome measures

*Primary endpoints
Consent was obtained for 3 of 16 patients, and the "dialysis rehabilitation (nutritional therapy + exercise therapy)" indicated in this study was implemented. No improvement in sarcopenia, the primary endpoint, was obtained, but we believe this was largely due to the sample size.

*Secondary endpoints
Secondary endpoints were as follows: changes in various blood data (including high-sensitivity C-reactive protein, abnormal glucose and lipid metabolism), lower limb muscle mass, upper limb muscle mass, skeletal muscle index (limb muscle mass (kg)/height (m) squared), upper arm circumference and subcutaneous fat thickness, upper arm muscle area, MIS (Malnutrition Inflammation Score), GNRI (Geriatric Nutritional Risk Index), and QIDS-J (Quick Inventry of Depressive Symptomatology).
Although it is difficult to evaluate changes over time in the secondary endpoints described in the previous section due to the small sample size, at least no significant increase or decrease was indicated.

*Other considerations
The remaining 13 patients continued only 3 months of exercise therapy, which resulted in a significant improvement in gait speed, independent of the presence or absence of sarcopenia.
This subanalysis was published by the collaborators and is a valuable report of the effect of short-term exercise therapy in the dialysis unit under COVID-19 (Koki Abe, et al. Ren Replace Ther. 2020; 6(1): 36).

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 10 Month 10 Day

Date of IRB

2019 Year 10 Month 10 Day

Anticipated trial start date

2020 Year 02 Month 01 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2022 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2020 Year 01 Month 09 Day

Last modified on

2023 Year 01 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044597


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name